Fig 1.

Kinetics of response for individual patients with (A) diffuse large B-cell lymphoma (DLBCL), (B) follicular lymphoma (FL), (C) mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), and (D) peripheral T-cell lymphoma (PTCL) who were treated with nivolumab 3 mg/kg. The horizontal line at –50 indicates the threshold for defining an objective response in DLBCL, FL, MF-CTCL, and PTCL. Most objective responses were sustained. The DLBCL and FL groups had individuals with responses maintained beyond 88 weeks. (closed square) first response; (X) first occurrence of new lesion.